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Cationic poly(amidoamine) promotes cytosolic
delivery of bovine RNase A in melanoma cells,
while maintaining its cellular toxicity†
Julie L. N. Dubois‡ and Nathalie Lavignac*
Ribonucleases are known to cleave ribonucleic acids, inducing cell death. RNase A, a member of the
ribonuclease family, generally displayed poor in vitro activity. This has been attributed to factors such as
low intracellular delivery. Poly(amidoamine)s have been used to promote the translocation of non-
permeant proteins to the cytosol. Our objective was to demonstrate that poly(amidoamine)s could
potentially promote the delivery of RNase A to selected cell line. Interactions of three cationic
poly(amidoamine)s (P1, P2 and ISA1) with wild-type bovine RNase A were investigated using gel
retardation assays, DLS and microcalorimetry. Although the polymers and the protein are essentially
cationic at physiological pH, complexation between the PAAs and RNase A was observed. The high
sensitivity differential scanning calorimetry (HSDSC) thermograms demonstrated that the thermal
stability of the protein was reduced when complexed with ISA1 (Tmax decreased by 6.5 1C) but was not
affected by P1 and P2. All the polymers displayed low cytotoxicity towards non-cancerous cells (IC50 4
3.5 mgmL1). While RNase A alone was not toxic to mouse melanoma cells (B16F1), P1 was able to
promote cytosolic delivery of biologically active RNase A, increasing cell death (IC50 = 0.09 mgmL
1).
Introduction
Studies in the early 1950s reported the anticancer activity of
high doses of bovine ribonuclease A (RNase A).1 However, over
the years, the cytotoxicity of RNase A has been controversial and
efforts have been made to develop more potent ribonucleases
such as Onconase. Still, Onconase is of non-mammalian origin
and is known to display some nephro- and neurotoxicity.2 The
low efficiency of RNase A has been attributed to poor intra-
cellular delivery, inhibition by the ribonuclease inhibitor (RI)
and short half-life.2 Bovine seminal RNase (BS-RNase) is a
naturally occurring dimeric ribonuclease.3 It is composed of
two subunits (M), which are either linked by simple disulphide
bonds (MQM form) or via additional non-covalent inter-
actions, resulting from the swapping of the N-terminal a-helices
(MM form). These dimeric structures favour evasion from the RI
and confers enhanced cytotoxicity to the MM form, more stable
under the reducing environment of the cytosol.3
Although dimerisation may not always grant the highest
cytotoxicity,4 strategies to obtain RI resistant RNase A, have led
to the synthesis of dimeric RNase A endowed with different
degree of cytotoxicity3,5–8. Microinjection of ribonuclease A into
the cytosol of Xenopus oocytes and NIH/3T3 cells confirmed its
cytotoxicity and demonstrated that the protein was potent at
low doses.9,10 More recent studies have revealed that enhanced
cytosolic delivery can compensate the inhibitory action of the RI.11,12
To that effect, different methods such as cationisation13–17 or
conjugation to non-biodegradable synthetic polymers18–20 have
been developed. Encouraging results were obtained but the
catalytic activity of the ribonuclease bioconjugates was often
decreased.15,16
Poly(amidoamine)s (PAAs) are biodegradable polymers and
are generally less cytotoxic compared to most polycations used
as nanocarriers.21 They are synthesised by Michael addition
polymerisation and possess secondary or tertiary amines in the
polymer backbone. Poly(amidoamine)s are pH-responsive poly-
electrolytes and upon acidification of their environment their
conformation will change from a coiled structure to a more
extended structure with increased radius of gyration. This pH
responsiveness has also been observed in a biological environ-
ment and increased haemoglobin release has been noticed at
acidic pH when red blood cells were incubated with some
poly(amidoamine)s.21 The capacity of the PAAs to be protonated
at acidic pH allows them to potentially destabilise the endosomal
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or lysosomal membranes and act as endosomolytic (or lysosomo-
lytic) polymers.22 Hence, some poly(amidoamine)s have been used
to promote the cytosolic delivery of drugs21,23 and biomacromole-
cules,24–26 including non-permeant toxins27–29 i.e. protein toxins
which are not able to translocate to the cytosol of the cells.
We recently synthesised some cationic poly(amidoamine)s
able to interact with and stabilise BSA.30 We hypothesised that
these PAAs could be used to promote the translocation of wild-
type RNase A into the cytosol of the cells. Using gel retardation
assays and high sensitivity differential scanning calorimetry
(HSDSC), we evaluated the interaction of the polymers with
the protein. The complexes obtained upon incubation were
characterised by DLS. The cellular uptake of the protein in
presence or absence of the PAAs was evaluated at 37 1C and 4 1C
using flow cytometry. RNase A induces cell death by cleaving
RNA located in the cytosol. The retention of its biological
activity and the cytosolic delivery of the protein was determined
indirectly by measuring the cells viability following incubation
with the PAA/RNase A complexes, using a non-toxic concen-
tration of RNase A.
Results and discussion
Cytotoxicity of the synthesised poly(amidoamine)s
The poly(amidoamine)s used in this study were synthesised by
Michael-type polyaddition (Table 1). P1 and P2 were derived
from the structure of ISA1 to modulate the polymer chain
flexibility and hydrophobicity. We previously demonstrated that
the polymers were cationic at physiological pH.30 Polycations tend
to display relatively high cytotoxicity, which often make them
unsuitable carriers for macromolecule delivery, especially if a
biological function needs to be restored.31,32 Ribonuclease A
possesses some potential anticancer activity, however cancer-
ous cells are not appropriate model cell lines to evaluate the
biocompatibility of nanocarriers, as they are known to display
different sensitivity compare to healthy cells. Therefore, in
order to evaluate the potential biocompatibility of the PAAs,
the cytotoxicity of the polymers towards non-cancerous cells
was evaluated. Their effect on the metabolic activity of HEK293
cells was assessed by measuring the mitochondrial activity after
24 h incubation. The viability of the cells was concentration-
dependent (Fig. 1). The PAAs were not toxic (i.e. viability
470%)33 up to a concentration of 1 mgmL1. All IC50 were
above 3.5 mgmL1 (Table 1) which is lower than for polycations
such as poly(ethyleneimine)32 and is similar to what has been
reported for other poly(amidoamine)s.21 No significant influence
of the polymer chemical structures was noticed. P2 seemed to
display a lower IC50 value, whichmay be attributed to the smaller
molecular weight for this polymer, however the difference was
not significant. Lactate dehydrogenase (LDH) release assay has
also been used as a measure of cell viability and gives additional
information to mitochondrial activity-based assays.34 It can be
used to evaluate the integrity of the cell membrane and reflect
the damage caused by the polymers. Peng et al.35 evaluated the
interaction of PAA/DNA polyplexes with bone marrow stromal
Table 1 Physicochemical30 and biological properties of the poly(amidoamine)s
Polymers
Mw Mn
PDI a z (mV)
IC50 LDH20
(g mol1) (g mol1) (mg mL1) (mg mL1)
P1 10 400 5100 2.0 27.6  0.2 6.0 0.5
P2 5700 3000 1.9 26.6  0.4 3.5 0.4
ISA1 16 300 8200 2.0 27.6  0.5 4.5 1
Mw: weight average molecular weight; Mn: number average molecular weight; PDI: polydispersity index; z: zeta potential.
a Mean value of two
independent replicates  SEM; IC50 represents the PAAs concentration at which 50% of the cell population is dead relative to untreated control
cells. LDH20 represents the PAAs concentration at which 20% of LDH is released relative to control cells treated with triton X100.
Fig. 1 Cytotoxicity of the synthesised poly(amidoamine)s (ISA1 (.), P1 (’)
and P2 (K)) was assessed using HEK293 cells (105 cells per well). Panel (a):
viability of the cells estimated at 24 h using an MTS assay. Panel (b):
membrane integrity of the cells estimated at 24 h using an LDH release
assay. Mean values  SEM, n = 6.
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cells and reported low percentage of LDH release (i.e.o10%) at
low N/P ratio. However, polyplexes may display lower cytotoxi-
city. We measured the LDH released after 24 h in presence of the
PAAs alone and found it was also concentration-dependent
(Fig. 1) with LDH20 above 0.4 mg mL
1 (Table 1). LDH10, the
PAAs concentration at which only 10% of LDH is released, was
determined for P2 (0.09 mg mL1) and ISA1 (0.28 mg mL1)
indicating the destabilising effect of these two polymers was
lower in comparison to P1.
Interaction of the poly(amidoamine)s with RNase A
Interactions between polyelectrolytes and proteins are generally
due to electrostatic forces.36 Evidence of complex formation, at
physiological pH, between the cationic poly(amidoamine)s and
BSA (pI B 4.7), an acidic model protein, has been reported.30
RNase A is a 13.7 kDa basic protein (pIB 9.5).37,38 Contrary to
BSA, it has an overall cationic charge at physiological pH. The
mobility of RNase A in an agarose gel retardation assay was
progressively altered with increasing PAA : RNase A weight
ratios (Fig. 2) suggesting some complexation despite repulsive
forces between the protein and the polyelectrolytes. It is usually
considered that complex formation between two macromolecules
requires opposite net charges. However, complexation between
macromolecules bearing similar net charges (i.e. both anionic or
both cationic) has been reported.39–41
In general, this has been attributed to the anisotropic distribu-
tion of the charges on the protein surface which, depending on
the nature of the protein, leads to the formation of either positive
or negative ‘‘patches’’.42 Such ‘‘negative patches’’ have been
observed for RNase A using computer modelisation39,43 and
make binding of the positively charge protein to cationic PAAs
possible (Fig. 3). Although Coulombic forces are considered the
driving force for protein/polymer interactions, the role of
hydrophobicity has also been demonstrated.44,45 ‘‘Hydrophobic
patches’’ on the surface of RNase A have been identified46,47
and could also be involved in its association with the poly-
(amidoamine)s via hydrophobic interactions (Fig. 3).
The size of the complexes were initially measured at PAA :
RNase A 500 : 1 weight ratio for which full retardation was
observed. The results, reported as size distribution by intensity,
indicated the presence of a heterogeneous population of poly-
disperse nanoparticles with some potential aggregation (Fig. 4).
Although full retardation of the protein was not achieved at
lower weight ratios (Fig. 2), a number of additional peaks in the
10 to 100 nm range were observed by DLS for all the polymers.
These peaks suggested the formation of small complexes and
indicated an increase in the heterogeneity of the samples.
The interaction of RNase A with the poly(amidoamine)s was
further investigated by microcalorimetry. High sensitivity DSC
is generally used to monitor protein thermal unfolding under
different experimental conditions. The denaturation tempera-
ture at maximum transition (Tmax) is an indicator of the protein
thermostability and depends on factors such as the ionic
strength or the pH of the samples.36 The higher Tmax is, the
more stable the protein is. The thermal stability of RNase A has
been evaluated in different environments and Tmax values
ranging from 56.5 to 63.9 1C have been reported.37,48–50 Under
our experimental conditions, Tmax was measured at 63.3 1C
(Fig. 5 and Table 2) with a corresponding unfolding enthalpy of
382.3 kJ mol1. DSC can also be used to investigate the thermal
denaturation of proteins in complexes. While some studies
have demonstrated that polymers can promote or maintain the
thermal stability of model proteins,51,52 others have reported
a destabilisation effect.36,53,54 Glycosylation, trimethylamine
Fig. 2 Complexation of RNase A–OG with the poly(amidoamine)s at
different PAA: RNase A weight ratios (w/w). Lane (1) RNase A alone; (2)
10 : 1; (3) 50 : 1; (4) 100 : 1; (5) 200 : 1; (6) 500 : 1; (7) 1000 : 1; (8) 2000 : 1.
Fig. 3 Ribbon representation of bovine RNase A (PDB: 1kf5) and modelisa-
tion of the electrostatic potential and hydrophobic patches. Positive and
negative potential patches are represented in blue and red, respectively.
Hydrophobic patches are represented in green. The black circle indicates
the binding cavity of the protein (see ESI† for 3D animated structure).
Fig. 4 DLS characterisation of the complexes. [RNase A] = 25 mg mL1;
PAA : RNase A complexes were prepared at 500 : 1 (w/w) ratio. Values
represent the modal size  width of the peak, n = 3.
Fig. 5 DSC profiles following normalisation and baseline correction of
RNase A alone (green) and in the presence (blue) of (a) ISA1; (b) P1 or (c) P2.
Heating rate 1 1C min1; [RNase A] = 0.5 mg mL1; PAA : RNase A
complexes were prepared at ratio 10 : 1 (w/w).
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N-oxide (TMAO) and lipids48,50,55 have improved the thermal
stability of RNase A to different extent, whereas complexation
with polyanions such as heparin or adsorption on silica nano-
particle had essentially a negative effect.37,38
In a previous study, we demonstrated that P1 and P2 could
stabilise BSA, whereas ISA1 had an adverse effect.30 The influence
of the poly(amidoamine)s on the thermal stability of RNase A, was
investigated under similar conditions (Fig. 5). The temperature at
maximum transition for RNase A, decreased by 6.5 1C in the
presence of ISA1 (Table 2). This is similar to what we previously
observed with BSA, although in the case of RNase A the width of
the peak at half maximum transition (DT) remained constant,
suggesting no intermediate in the unfolding process.37 On the
contrary, Tmax was not affected in the presence of P1 or P2
indicating RNase A maintained its thermal stability (Table 2).
We previously found that P1 and P2 displayed increased chain
flexibility in comparison to ISA1.30 The increased rigidity of the
polymer backbone could potentially explain that under similar
experimental conditions, ISA1 destabilises the protein. Further
analysis of all the thermograms assuming a two-state model of
denaturation (Native protein# Unfolded protein), demonstrated
the equivalence of the calorimetric and Van’t Hoff enthalpies,
which further confirmed the absence of intermediate. This also
indicated some cooperativity in the unfolding process of RNase A
(i.e. n = dHv/DHcalB 1) and has been previously observed for the
native protein or in presence of TMAO and lipids.48,50
Complex formation between cationic poly(amidoamine)s
and an acidic protein revealed that in some cases, the activity
of the protein could be inhibited.24 We therefore assessed
whether the enzymatic activity of RNase A would be altered
upon interaction and complexation with our poly(amidoamine)s
(Fig. 6). Yeast RNA was incubated for 30 min. at 37 1C in the
presence or absence of RNase A. The enzyme was able to degrade
the ribonucleic acids in the absence or in the presence of the
poly(amidoamine)s, even at higher ratio corresponding to full
complexation of the protein (Fig. 2) indicating the catalytic site
of RNase A was accessible to the substrate.
Cellular uptake and cytotoxicity of RNase A
Ribonucleases capable to reach cellular ribonucleic acids are
known to induce cell death.2 Although the intracellular path-
way of RNase A is still subject to discussion, some aspects have
been identified.56 However, following interaction with the cell
membrane and endocytosis, only a small amount of RNase A
reaches the cytosol where it eventually binds the ribonuclease
inhibitor (RI).57 After binding, the catalytic activity of RNase A
is totally inhibited due to obstruction of its active site, hence
eliminating any cytotoxic effect. B16F1 cells were initially subjected
to increasing concentration (0–100 mg mL1) of wild-type RNase A.
As expected, no effect on the viability of the cells was observed
(Fig. 7c – red line). Aside from direct cytosolic injection,9,10
Table 2 Thermodynamic properties of RNase A in the absence and presence of the PAAs
Tmax (1C) DHcal (kJ mol
1) DScal (kJ mol
1 K1) dHV (kJ mol
1) n DT (1C)
RNase A 63.320.02 382.330.3 1.140.09 396.611.8 1.040.05 7.50.2
P1 : RNase A 63.110.02 426.77.9 1.270.02 408.14.5 0.960.01 7.90.0
P2 : RNase A 63.130.00 419.15.7 1.250.02 404.61.4 0.970.02 7.60.3
ISA1 : RNase A 56.810.12 353.516.2 1.070.05 363.66.3 1.030.03 8.20.0
Tmax: temperature of denaturation. Tmax was determined as the temperature corresponding to the maximum heat capacity (Cp); DHcal: calorimetric
enthalpy change; DScal: calorimetric entropy change; dHV: Van’t Hoff enthalpy change; n: cooperative units; DT: width at half maximum. Mean
value of two independent replicates  SEM.
Fig. 6 Enzymatic activity of RNase A in the absence or presence of
poly(amidoamine)s. Lane (1) RNA alone; (2) RNA + RNase A; Lanes (3–8)
RNA + PAA : RNase A at different weight ratios: (3) 1 : 1; (4) 5 : 1; (5) 10 : 1; (6)
50 : 1; (7) 100 : 1; (8) 500 : 1.
Fig. 7 Intracellular delivery and cytotoxicity of RNase A. Panels (a), (b) and
(c) show the viability of B16F1 cells (104 cells per well) at 48 h following 5 h
incubation with poly(amidoamine)s ISA1 (a), P1 (b) and P2 (c) in the absence
(green) or presence (blue) of a non-toxic concentration of RNase A
(25 mg mL1). Panel (d) shows the corresponding IC50 in the absence (green)
or presence (blue) of RNase A; IC50 values were determined by nonlinear
regression using a sigmoidal dose–response curve (eqn (2)) (goodness of fit,
R2 4 0.9 for all fits). Panel (c) also shows the viability of B16F1 with
increasing concentration of RNase A (red). Mean values  SEM, n = 6.
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most approaches to improve the efficiency of RNase A have
involved the development of RI evasive mutant proteins.57
However, a few techniques involving the chemical derivatisa-
tion of RNase A, including cationisation, have been used with
varied success.15–20 More recently, an alternative method has been
developed to co-incubate RNase A with PAMAM dendrimers58
but under the experimental conditions reported, only RNase A
variants were successfully delivered. Poly(amidoamine)s are
endosomolytic polymers and have been used to promote the
intracellular delivery of macromolecular drugs such as plasmid
DNA, siRNA and proteins.21,22 RNase A exerts its cytotoxicity by
cleavage of cytosolic RNA, which requires escape from the
endosomes to the cytosol.
Hence, to assess the ability of the synthesised linear poly-
(amidoamine)s to deliver RNase A inside the cytosol, B16F1
cells were incubated for 5 h with the polymers alone or the
complexes. The complexes were prepared using a non-toxic
concentration of RNase A and different PAA : RNase A weight
ratios. Following removal of the complexes, the cell viability
was assessed at 43 h post-transfection using an MTS assay.
Concentrations of 5 and 10 mgmL1 of RNase A were initially
used but no effect was observed (data not shown). The concen-
tration was increased to 25 mg mL1 (Fig. 7). Comparison of the
IC50 values obtained for the polymers alone and the complexes
demonstrated that for P2 no increase in cytotoxicity was
observed (Fig. 7c and d). ISA1, which has been previously used
to deliver non-permeant proteins,27–29 seemed to be more
efficient as a decrease of the IC50 was noticed for the complexes
(Fig. 7a and d). However, the difference was considered not
significant ( p4 0.005). P1 was the only poly(amidoamine) able
to induce efficient intracellular release of RNase A, as indicated
by a significant two-fold increase of the complexes cytotoxicity
(IC50 = 0.09 mg mL
1; p o 0.005) (Fig. 7b and d). To further
investigate the cellular delivery of wild-type RNase A by the
PAAs, we used a protein labelled with oregon green (OG) and
incubated the B16F1 cells with complexes prepared at different
PAA/RNase A–OG weight ratios (RNase A–OG: 25 mg mL1),
selected to match different sections of the dose–response
curves (Fig. 7a–c – vertical dotted black lines). The cell asso-
ciated fluorescence (CaF) at 37 1C was quantified after 5 h using
flow cytometry (Fig. 8). At this temperature, the observed
fluorescence corresponded to the fraction of protein taken up
by the cell via endocytosis but also to the protein simply
adsorbed on the external surface of the cell membrane. This
latter non-specific binding (NSB) can be estimated by reducing
the metabolic activity of the cells at low temperature, inhibiting
endocytosis.59,60 NSB was quantified at 4 1C and was sub-
sequently subtracted to determine the total uptake of the protein
at 37 1C.22 All the polymers promoted increased delivery of the
protein at all ratios. Uptake of the protein increased with the
proportion of PAA levelling off at higher ratios, perhaps indicat-
ing some saturation of the intracellular pathway.
The use of wild-type RNase A as a potential therapeutic agent
has been essentially impaired due to its inefficient intracellular
delivery and inhibition by the RI.2 However, some studies have
recently demonstrated that RI evasion might not be the only
prerequisite to induce some cytotoxicity, improving translocation
of the protein into the cytosol after endocytosis could be sufficient
to saturate the RI.11,12 Although, P2 was able to promote cellular
uptake of the protein to similar level as P1 (Fig. 8) we did not
observe any increased toxicity for the delivery of RNase A with this
polymer (Fig. 7c). The mechanism by which poly(amidoamine)s can
promote macromolecule translocation into the cytosol of the cells
has not been fully elucidated. However, it is generally considered
that the buffer capacity of the polymer is an important factor.21 The
‘‘proton sponge effect’’ is the current standard theory to explain the
endosomolytic properties of most polycations.61 The hypothesis
relies on the buffer capacity of the polymers, higher buffer capacity
corresponding to higher transfection efficiency. P2 displayed a lower
buffer capacity in comparison to both P1 and ISA1,30 this seems to
have impaired its endosomolytic capacity and potentially limited the
cytoplasmic translocation of RNase A. On the contrary, the efficiency
of ISA1 seemed to be limited not by its buffer capacity, similar to P1,
but by its ability to promote cellular uptake significantly lower than
both P1 and P2 (Fig. 8b). The amount of protein reaching the cytosol
may not have been appropriate to saturate the RI to a significant
extend. The results observed in the presence of P1 indicated
sufficient amount of RNase A was delivered into the cytosol of the
B16F1 cells to increase cell death (Fig. 7b). However, at the ratios for
which the effect is observed, a population of complexes co-exist with
free protein. It is therefore likely that the intracellular delivery taking
place is promoted by both complexation with P1 and the effect of
the polymer and/or complexes ‘‘in trans’’. Overall, our results
indicate that a minimum concentration of RNase A was required
to observe an effect and correlate with previous observations
indicating that provided the appropriate amount of RNase A reaches
the cytosol, the RI could be saturated.11,12
Experimental
Materials
RNase A from bovine pancreas, NaCl and triton X-100 were from
Sigma (Gillingham, UK). TRIS buffer, nicotinamide adenine
Fig. 8 Cellular uptake of fluorescently labelled RNase A (25 mg mL1) at
several PAA/RNase A (w/w) ratios: ISA1 (red), P1 (green) and P2 (blue). Panel
(a) shows the B16F1 (105 cells per well) cell associated fluorescence at
37 1C (dashed lines) and 4 1C (dotted lines) after 5h incubation. Total
uptake at 37 1C (plain lines) was calculated by subtracting values at 4 1C.
Panel (b) shows the total uptake at 37 1C normalised to the uptake of
RNase A alone. Mean values  SEM, n = 6, *** p o0.001.
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dinucleotide (NAD), HEPES, D-glucose, DMSO, HCl, phenazine
methosulfate (PMS) and TAE were from Fisher (Loughborough,
UK). Sodium-L-lactate was from Alfa Aesar (Heysham, UK).
Iodonitrotetrazolium salt (INT) was from TCI (Zwijndrecht,
Belgium). Agarose was from Roche (Burgess Hill, UK). DMEM,
RPMI-1640, DPBS, FBS, penicillin/streptomycin/glutamine (PSG),
minimum essential medium non-essential amino acids (MEM
NEAA) and succinimidyl ester oregon green 488 (OG) were from
Life Technologies (Paisley, UK). 3-(4,5-Dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
was from Promega (Mannheim, Germany). Mouse melanoma
(B16F1) and human embryonic Kidney 293 (HEK293) cells were
from the European Collection of Cell Cultures. The synthesis and








Agarose gel retardation assay. Samples of PAA : RNase A–OG
were prepared by mixing 18.7 mL of PAAs (2.4–480 mg mL1 in
10 mM HEPES, pH = 7.4, 5 wt% D-glucose) with 3.8 mL of RNase
A–OG (1.18 mg mL1). The mixtures were left at room tempera-
ture (r.t.) for 30 min. and 21.5 mL of HEPES buffer was added.
Samples were applied onto a 0.7% (w/v) agarose gel. Electrophoresis
was run at 60 V for 45 min. in a 1 TAE buffer. RNase A–OG was
visualised using a G:BOX transilluminator (Syngene). Free protein
was used as a control. [Oregon green (OG) labelling of RNase A
(RNase A–OG) was carried out according to Life Technologies
protocol (degree of labelling found: 0.33 mol OG mol1 RNase
A). No free dye was detected following thorough purification by
PD10 column and ultracentrifugation (MWCO 3 kDa)].
High sensitivity differential scanning calorimetry. Thermal
stability of RNase A was determined using a Nano DSC micro-
calorimeter (TA Instruments) equipped with capillary cells
(300 mL). PAA : RNase A samples at ratio 10 : 1 (w/w) were
prepared by mixing RNase A (400 mL, 2.5 mg mL1, 10 mM
HEPES pH = 7.4, 0.15 M NaCl) with appropriate PAA solutions
(1.6 mL, 6.25 mg mL1, 10 mM HEPES pH 7.4, 0.15 M NaCl).
Final concentration of RNase A was 0.5 mg mL1. The samples
were left at room temperature for 30 min. and were degassed
for 10 min., at 10 1C and under vacuum (23 mmHg). During the
analysis, a pressure of 4 atm was applied over the reference and
sample cells. Thermograms were recorded from 10 1C to 100 1C
with a scanning rate of 1 1C min1. Data were analysed using
the Launch Nanoanalyze software from TA Instrument. No thermal
transition were detected for the PAAs alone.30
Dynamic light scattering. Measurements were carried out at
25 1C using a nanoZS zetasizer (Malvern). Complexes were
prepared as previously described at PAA : RNase A (w/w) ratios
from 10 : 1 to 500 : 1 with an RNase final concentration of
25 mgmL1. In order to increase the resolution of the peak
observed, the analysis of the results was carried out using
narrow mode.
Enzymatic activity. Complexes (11 mL) were prepared as
previously described at PAA : RNase A (w/w) ratios from 1 : 1 to
500 : 1 using 40 ng of RNase A. The mixtures were left at r.t. for
30 min. 4 mg of RNA (5 mL, 0.8 mg mL1) were added and the
samples were further incubated for 30 min. at 37 1C. Samples
were then applied onto a 1% (w/v) agarose gel. Electrophoresis
was run at 40 V for 30 min. in a 1 TAE buffer. The gels were
stained for 30 min. in 200 mL of 1 TAE buffer containing
ethidium bromide (0.5 mg mL1) and visualised using the
transilluminator.
Cells and culture conditions. HEK293 cells were cultured in
DMEM supplemented with 10% FBS, 1 PSG and 1  MEM
NEAA. B16F1 cells were cultured in RPMI supplemented with
10% FBS and 1 PSG. All cells were maintained in a humidified
5% CO2-containing atmosphere at 37 1C and passaged when
reaching 80% confluence.
Cytotoxicity of the PAAs. HEK293 cells (105 cells per well)
were seeded in 96-well plates. After 24 h, the medium was
replaced by filtered (0.2 mm) polymer solutions (100 mL;
0–20 mg mL1) and fresh medium (100 mL). MTS assay: After
21 h incubation, PAAs solutions were removed and fresh
medium without FBS was added (200 mL). MTS : PMS reagent
(20 mL; 2:0.92 mg mL1 in DPBS) was added and cells were left
at 37 1C for 3 h. Absorbance was read at 492 nm. Viability was
expressed as percentage of untreated control cells. IC50 values
were determined graphically. LDH release assay: After 24 h
incubation, the cells were centrifuged at 1000 rpm for 5 min.
and 100 mL of the supernatant was transferred to clean 96-well
plates. 90 mL of fresh reagent I and 10 mL of fresh reagent II
were sequentially added to each well [reagent I: sodium-L-
lactate (800 mL; 0.54 mM), NAD (800 mL; 1.30 mM) diluted into
5.6 mL TRIS buffer (0.2 M) pH = 8.2; reagent II: INT in DMSO
(1 mL; 66 mM) and PMS in TRIS buffer (1 mL; 28 mM)]. The
plates were incubated for 30 min. in the dark and at room
temperature. The reaction was stopped by adding 15 mL of HCl
(1 M). Absorbance was read at 492 nm. LDH release was
expressed as percentage release (1) relative to control cells
treated with 2% triton X (TX) and LDH20/10 values were deter-
mined graphically.
% ¼ AAuntreated cells
ATX treated cells Auntreated cells  100 (1)
Cytotoxicity of RNase A. B16F1 cells (104 cells per well) were
seeded in 96-well plates. After 24 h, the medium was replaced
by fresh medium (100 mL). 100 mL of filtered (0.2 mm) RNase A
solutions (0.2 ng mL1–200 mg mL1) or polymer solutions
(0–40 mg mL1) without or incubated with RNase A (30 min. at
r.t.; 25 mg mL1 final concentration) were added to the cells.
After 5 h of incubation at 37 1C, the solutions were removed and
fresh medium (200 mL) was added. Following a further 40 h, an
MTS assay was carried out as described above. IC50 values were
determined by nonlinear regression using a sigmoidal dose–
response curve and eqn (2) with a slope h = 2 as a constraint
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(goodness of fit, R24 0.9 for all fits). Data represent mean value
of two independent experiments with triplicates and were
further analysed using an unpaired t-test to calculate two-tailed
p values with a confidence of interval set as 99%. IC50 were
considered significantly different if po 0.005 (GraphPad Prism).
Y ¼ Bþ T  Bð Þ
1þ 10ððLogEC50XÞhÞ (2)
where B and T are the bottom and the top of the curve,
respectively and h the Hill slope.
Cellular uptake. B16F1 cells (105 cells per well) were seeded
in 24-well plates. After 24 h, the medium was replaced (200 mL)
and 200 mL of PAA : RNase A–OG complexes (1 : 1 to 50 : 1 (w/w)
ratios; 25 mg mL1 RNase A–OG final concentration) were
added. The cells were incubated at 37 1C for 5 h, rinsed with
ice-cold PBS and recovered by trypsinisation. The samples were
then centrifuged for 3 min at 800 g. The supernatant was
removed and the cells suspended in ice-cold PBS (300 mL) for
analysis by flow cytometry. For each sample 10 000 events were
acquired, untreated cells were used as reference and RNase A–OG
and polymer solutions were used as control. The same experi-
ments were also conducted at 4 1C in which case the cells were
left at 4 1C for 1 h prior addition of the complexes. The cellular
uptake was calculated using eqn (3).
Uptake ¼ CaFð Þ37C  CaFð Þ4C (3)
where CaF represents the cell associated fluorescence at 37 1C or
4 1C calculated as previously described.22
Protein surface modelling. Modelisations were carried out
using the Swiss-Pdb viewer (v4.1.0). Coordinates for RNase A
were those deposited in the Protein Data Bank (PDB) as data set
‘‘1KF5’’.62 The electrostatic potential surrounding RNase A was
calculated by the Poisson–Boltzmann equation using a dielectric
constants of 2 for the protein interior, 80 for the solvent region
and an ionic strength of 0.15 mM.
Conclusions
We demonstrated the ability of linear cationic poly(amidoamine)s
ISA1, P1 and P2 (z = + 26.6 to + 27.6 mV at pH 7.4) to interact with
RNase A on the ‘‘wrong side’’ of the isoelectric point due to the
presence of ‘‘negative patches’’ on the surface of the protein at
physiological pH. Upon interaction, a heterogeneous population
of nanocomplexes (10 to 100 nm) were observed. Microcalori-
metry further indicated that at PAA : RNase A - 10 : 1 (w/w) ratio,
P1 and P2 did not destabilise RNase A whereas ISA1 did. Upon
24 h incubation all the PAAs displayed low cytotoxicity towards
non-cancerous cells (IC50 = 3.5 to 6 mg mL
1; LDH20 = 0.5 to
1 mg mL1). Free wild-type RNase A was not toxic to B16F1 cells
up to a concentration of 100 mg mL1. However, when complexed
with P1, increased cytotoxicity and cellular uptake was observed
indicating that P1 was able to promote intracellular delivery of
biologically active RNase A (IC50 = 0.09 mg mL
1) and potentially
helped to bypass or overpower the inhibitory action of the RI
found in the cytosol of most cells.
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